| Entry |
|
|---|
| Name |
Buformin (USAN/INN) |
|---|
| Formula |
C6H15N5
|
|---|
| Exact mass |
157.1327
|
|---|
| Mol weight |
157.2168
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG00114): | D02206<JP> |
|
|---|
| Efficacy |
Antidiabetic, Hypoglycemic |
|---|
| Comment |
Biguanide
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04920 | Adipocytokine signaling pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BA Biguanides
A10BA03 Buformin
D00595 Buformin (USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01685 Insulin sensitizer
DG01684 Biguanide antidiabetic
DG00114 Buformin
D00595 Buformin
DG02044 Hypoglycemic agent
DG01684 Biguanide antidiabetic
DG00114 Buformin
D00595 Buformin
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
CAMK group
AMPK (PRKAA)
D00595 Buformin (USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01685 Insulin sensitizer
DG01684 Biguanide antidiabetic
DG00114 Buformin
DG02044 Hypoglycemic agent
DG01684 Biguanide antidiabetic
DG00114 Buformin
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 11
1 N1b N 21.2128 -16.3163
2 C2c C 19.9976 -17.0197
3 C1b C 22.4221 -17.0197
4 N1b N 18.7881 -16.3163
5 N2a N 19.9976 -18.4210
6 C1b C 23.6372 -16.3163
7 C2c C 17.5788 -17.0197
8 C1b C 24.8465 -17.0197
9 N1a N 16.3695 -16.3163
10 N2a N 17.5788 -18.4210
11 C1a C 26.0501 -16.3163
BOND 10
1 1 2 1
2 1 3 1
3 2 4 1
4 2 5 2
5 3 6 1
6 4 7 1
7 6 8 1
8 7 9 1
9 7 10 2
10 8 11 1
|
|---|
